Third Dose of COVID-19 Vaccine Appears Least Effective for Lymphoma Patients
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
Researchers sought to determine the role of fibrinogen levels in patients with myelodysplastic syndrome.
Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.
Enasidenib did not improve overall survival, but it was associated with improvements in event-free survival and time to treatment failure.
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival.
Mosunetuzumab produced an objective response rate of 80%.
Researchers developed a clinical risk model for predicting outcomes of allogeneic transplant in patients with MDS.
Brentuximab vedotin prolonged progression-free survival and overall survival in patients with stage III/IV Hodgkin lymphoma.
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.